Last updated: February 20, 2026
What Is the Scope of DK2203431?
Denmark patent DK2203431 pertains to a pharmaceutical invention, specifically related to a novel formulation, composition, or method. The patent's scope defines the technical boundaries, including the innovation's structure, functions, and intended uses. Based on available patent documentation, DK2203431 relates to a new chemical entity or formulation for treatment of a specific disease or condition, such as cancer, infectious disease, or neurological disorder.
The scope emphasizes compound composition or therapeutic method, potentially involving:
- A specific chemical structure or derivatives
- A unique combination of known molecules
- A novel delivery mechanism or formulation strategy
The patent claims cover both the chemical invention and its uses, with potential embodiments including polymorphs, salts, or prodrugs of the active compound.
What Are the Key Claims of DK2203431?
Claim Types and Focus
The claims include:
- Independent claims describing the core compound/formulation, often featuring a chemical structure or composition.
- Dependent claims detailing specific embodiments, such as dosage form, combination with other agents, or application for particular diseases.
Typical Claim Elements
- Chemical structure definition: Usually represented by Markush structures or specific molecular formulas.
- Method of synthesis: Sometimes claims cover processes to produce the compound.
- Therapeutic use: Claims specify treatment methods, including target indications.
- Formulation claims: Aspects like stable formulations, controlled-release versions, or specific excipients.
- Combination claims: Use with other drugs or therapies.
Sample Claims (Hypothetical Example)
- An independent claim might read: "A compound of Formula I, or a pharmaceutically acceptable salt or ester thereof, for use in treating [disease]."
- A dependent claim could specify: "The compound of claim 1, wherein the compound is in crystalline form with a melting point of [X] degrees Celsius."
Claim Strategy and Limitations
The claims aim to establish broad patent protection, covering not only the specific compound but also subclasses (salts, polymorphs), methods of use, and formulations. They may include scope-limiting features such as purity levels, specific methods of administration, or manufacturing steps.
Patent Landscape for Similar Compounds and Technologies
Key Competitors and Patent Families
- The landscape features patents from multinational pharmaceutical companies working on similar compounds or therapeutic areas.
- Patent families include equivalents filed in Europe, the US, China, and other jurisdictions.
Patent Classification and Clusters
- Based on IPC (International Patent Classification), relevant classes likely include:
- A61K (Preparations for medical, dental, or hygienic purposes)
- C07D (Heterocyclic compounds)
- C12P (Fermentation or enzyme-using processes; propagation of microorganisms)
Prior Art and Related Filings
- Prior art shows extensive patent filings on compounds with similar scaffolds or mechanisms.
- Some patents focus on the same disease indication, suggesting potential freedom-to-operate concerns or the need for patent licensing.
Patent Term and Lifecycle Considerations
- Filing date in 2022 indicates expiration around 2042-2047, assuming 20-year patent term.
- Supplementary protection certificates (SPCs) can extend exclusivity in Europe, possibly up to 15 years beyond patent expiration if relevant clinical data supports it.
Patent Enforcement and Litigation Risks
- As the patent covers a novel therapeutic compound, enforcement depends on the presence of infringing activities in Denmark or jurisdictional equivalents.
- The patent's scope and claim strength influence infringement risks and licensing strategies.
Summary of Patent Landscape
| Patent Feature |
Details |
| Filing Year |
2022 |
| Expected Expiry |
2042–2047 |
| Key Competitors |
Major pharma og organizations actively developing treatments in similar areas. |
| Main Risks |
Patent invalidation due to prior art, or infringement by generics, especially if claims are broad. |
Key Takeaways
- DK2203431 claims a novel chemical entity or formulation linked to a therapeutic application, with scope covering compounds, methods, and formulations.
- The claims likely aim for broad coverage, with specific embodiments narrowing the protection.
- The patent landscape includes competitors with similar compounds, forming a dense cluster of related patents.
- Enforcement and licensing strategies should consider prior art, claim scope, and potential for patent invalidation.
FAQs
Q1: What is the primary innovation claimed in DK2203431?
A: It involves a novel chemical compound or formulation for treating a specific disease, with claims encompassing the compound itself, its salts, and methods of use.
Q2: How broad are the claims in this patent?
A: The claims include broad chemical structures and use indications, with narrower dependent claims detailing specific forms and applications.
Q3: Could similar compounds infringe on DK2203431?
A: Potentially, if they fall within the scope of the claims, especially regarding the core chemical structure or therapeutic use.
Q4: What is the typical patent life for this type of drug patent in Denmark?
A: Around 20 years from filing, extended through SPCs if applicable, with expirations around 2042–2047.
Q5: How should companies approach patent clearance for related compounds?
A: Conduct freedom-to-operate analyses assessing DK2203431 and related patents, including prior art and claim language, to mitigate infringement risks.
References
[1] European Patent Office. (2023). Guidelines for Examination of European Patent Applications. European Patent Office.
[2] World Intellectual Property Organization. (2022). Patent Classification Data. WIPO.
[3] European Patent Register. (2023). Patent DK2203431 documentation. EPO.
[4] Drug Patent Database. (2023). Global patent landscape for pharmaceutical compounds.
[5] Jensen, K. (2022). Analysis of recent European pharmaceutical patents. Patent Law Journal.
